ProCE Banner Activity

ENZAMET: Phase III Trial of SoC Therapy With or Without Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer

Slideset Download
Conference Coverage

Enzalutamide plus ADT significantly improved OS compared with standard nonsteroidal antiandrogen plus ADT in patients with mHSPC.

Released: June 06, 2019

Expiration: June 04, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro